73 drugs reach their earliest generic-entry date in 2034

Jan 2034 · 3

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Loreev Xr · 4 strengths lorazepam	lorazepam	Almatica	214826	8 Jan 2034	patent
Byfavo remimazolam besylate	remimazolam besylate	Acacia	212295	13 Jan 2034	patent, carve-out possible
Evomela melphalan hydrochloride	melphalan hydrochloride	Acrotech Biopharma	207155	30 Jan 2034	patent

Feb 2034 · 6

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Imvexxy · 2 strengths estradiol	estradiol	Mayne Pharma	208564	2 Feb 2034	patent, carve-out possible
Linzess · 3 strengths linaclotide	linaclotide	Abbvie	202811	16 Feb 2034	patent
Adempas · 5 strengths riociguat	riociguat	Bayer Hlthcare	204819	18 Feb 2034	patent
Forzinity elamipretide hydrochloride	elamipretide hydrochloride	Stealth Biotheraps	215244	28 Feb 2034	patent, carve-out possible
Mekinist · 2 strengths trametinib dimethyl sulfoxide	trametinib dimethyl sulfoxide	Novartis	204114	28 Feb 2034	patent
Tafinlar · 2 strengths dabrafenib mesylate	dabrafenib mesylate	Novartis	202806	28 Feb 2034	patent

Mar 2034 · 13

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Dilaudid · 5 strengths hydromorphone hydrochloride	hydromorphone hydrochloride	Fresenius Kabi Usa	019034	12 Mar 2034	patent
Dilaudid-Hp hydromorphone hydrochloride	hydromorphone hydrochloride	Fresenius Kabi Usa	019034	12 Mar 2034	patent
Morphine Sulfate · 3 strengths morphine sulfate	morphine sulfate	Fresenius Kabi Usa	204223	12 Mar 2034	patent
Soolantra ivermectin	ivermectin	Galderma Labs Lp	206255	13 Mar 2034	patent, carve-out possible
Exondys 51 · 2 strengths eteplirsen	eteplirsen	Sarepta Theraps Inc	206488	14 Mar 2034	patent, carve-out possible
Rayaldee calcifediol	calcifediol	Eirgen	208010	14 Mar 2034	patent
Rhopressa netarsudil mesylate	netarsudil mesylate	Alcon Labs Inc	208254	14 Mar 2034	patent
Rocklatan latanoprost; netarsudil dimesylate	latanoprost; netarsudil dimesylate	Alcon Labs Inc	208259	14 Mar 2034	patent
Spritam · 2 strengths levetiracetam	levetiracetam	Aprecia Pharms	207958	14 Mar 2034	patent
Tonmya cyclobenzaprine hydrochloride	cyclobenzaprine hydrochloride	Tonix	219428	14 Mar 2034	patent
Mimrylo · 5 strengths rusfertide acetate	rusfertide acetate	Takeda Pharms Am	220605	17 Mar 2034	patent
Natesto testosterone	testosterone	Acerus	205488	17 Mar 2034	patent, carve-out possible
Veozah fezolinetant	fezolinetant	Astellas	216578	28 Mar 2034	patent

Apr 2034 · 6

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Furoscix furosemide	furosemide	Scpharmaceuticals	209988	3 Apr 2034	patent
Viltepso viltolarsen	viltolarsen	Nippon Shinyaku	212154	3 Apr 2034	patent
Zevtera ceftobiprole medocaril sodium	ceftobiprole medocaril sodium	Istx	218275	3 Apr 2034	exclusivity
Omidria ketorolac tromethamine; phenylephrine hydrochloride	ketorolac tromethamine; phenylephrine hydrochloride	Rayner Surgical	205388	23 Apr 2034	patent
Rapiblyk landiolol hydrochloride	landiolol hydrochloride	Aop Hlth Us	217202	25 Apr 2034	patent, carve-out possible
Luzu luliconazole	luliconazole	Bausch	204153	28 Apr 2034	patent

May 2034 · 6

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Tryngolza (Autoinjector) · 2 strengths olezarsen sodium	olezarsen sodium	Ionis Pharms Inc	218614	1 May 2034	patent
Rybelsus · 3 strengths semaglutide	semaglutide	Novo	213051	2 May 2034	patent
Cypsedo cipepofol	cipepofol	Haisco	220482	6 May 2034	patent
Lodoco colchicine	colchicine	Agepha Pharma Fz	215727	9 May 2034	patent, carve-out possible
Alkindi Sprinkle · 4 strengths hydrocortisone	hydrocortisone	Eton	213876	12 May 2034	patent
Yonsa abiraterone acetate	abiraterone acetate	Sun Pharm	210308	20 May 2034	patent, carve-out possible

Jun 2034 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Baxdela delafloxacin meglumine	delafloxacin meglumine	Melinta	208611	2 Jun 2034	patent, carve-out possible
Trulance plecanatide	plecanatide	Salix	208745	5 Jun 2034	patent
Zavzpret zavegepant hydrochloride	zavegepant hydrochloride	Pfizer	216386	26 Jun 2034	patent
Parsabiv · 3 strengths etelcalcetide	etelcalcetide	Kai Pharms Inc	208325	27 Jun 2034	patent

Jul 2034 · 10

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Contrave bupropion hydrochloride; naltrexone hydrochloride	bupropion hydrochloride; naltrexone hydrochloride	Azurity	200063	2 Jul 2034	patent, carve-out possible
Imcivree setmelanotide acetate	setmelanotide acetate	Rhythm	213793	4 Jul 2034	patent
Izervay avacincaptad pegol sodium	avacincaptad pegol sodium	Astellas	217225	11 Jul 2034	patent, carve-out possible
Abraxane paclitaxel	paclitaxel	Bristol-Myers	021660	12 Jul 2034	patent
Jakafi Xr · 5 strengths ruxolitinib phosphate	ruxolitinib phosphate	Incyte Corp	217180	17 Jul 2034	patent
Epclusa · 2 strengths sofosbuvir; velpatasvir	sofosbuvir; velpatasvir	Gilead Sciences Inc	208341	30 Jul 2034	patent
Epclusa · 2 strengths sofosbuvir; velpatasvir	sofosbuvir; velpatasvir	Gilead Sciences Inc	214187	30 Jul 2034	patent
Harvoni · 2 strengths ledipasvir; sofosbuvir	ledipasvir; sofosbuvir	Gilead Sciences Inc	205834	30 Jul 2034	patent
Rizafilm rizatriptan benzoate	rizatriptan benzoate	Gensco	205394	30 Jul 2034	patent
Tembexa brincidofovir	brincidofovir	Emergent Biodefense	214460	30 Jul 2034	patent

Aug 2034 · 8

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Aubagio · 2 strengths teriflunomide	teriflunomide	Sanofi Aventis Us	202992	4 Aug 2034	patent
Ibrance · 3 strengths palbociclib	palbociclib	Pfizer	207103	8 Aug 2034	patent
Xarelto · 3 strengths rivaroxaban	rivaroxaban	Janssen Pharms	022406	17 Aug 2034	patent
Wainua eplontersen sodium	eplontersen sodium	Astrazeneca Ab	217388	25 Aug 2034	patent
Wainua (Autoinjector) eplontersen sodium	eplontersen sodium	Astrazeneca Ab	217388	25 Aug 2034	patent
Kloxxado naloxone hydrochloride	naloxone hydrochloride	Hikma	212045	26 Aug 2034	patent
Bosulif · 3 strengths bosutinib monohydrate	bosutinib monohydrate	Pf Prism Cv	203341	28 Aug 2034	patent
Bosulif · 2 strengths bosutinib monohydrate	bosutinib monohydrate	Pf Prism Cv	217729	28 Aug 2034	patent

Sep 2034 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Lumisight pegulicianine acetate	pegulicianine acetate	Lumicell	214511	14 Sep 2034	patent
Xeljanz Xr · 2 strengths tofacitinib citrate	tofacitinib citrate	Pfizer	208246	14 Sep 2034	patent
Idhifa · 2 strengths enasidenib mesylate	enasidenib mesylate	Bristol Myers Squibb	209606	16 Sep 2034	patent
Hepzato melphalan hydrochloride	melphalan hydrochloride	Delcath Systems Inc	201848	17 Sep 2034	patent

Oct 2034 · 3

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Givlaari givosiran sodium	givosiran sodium	Alnylam Pharms Inc	212194	3 Oct 2034	patent
Tembexa brincidofovir	brincidofovir	Emergent Biodefense	214461	10 Oct 2034	patent
Durysta bimatoprost	bimatoprost	Abbvie	211911	31 Oct 2034	patent

Nov 2034 · 6

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Dojolvi triheptanoin	triheptanoin	Ultragenyx Pharm Inc	213687	14 Nov 2034	patent
Synjardy · 4 strengths empagliflozin; metformin hydrochloride	empagliflozin; metformin hydrochloride	Boehringer Ingelheim	206111	17 Nov 2034	patent
Jadenu · 3 strengths deferasirox	deferasirox	Novartis Pharms Corp	206910	21 Nov 2034	patent
Sinuva mometasone furoate	mometasone furoate	Intersect Ent Inc	209310	24 Nov 2034	patent
Dificid fidaxomicin	fidaxomicin	Cubist Pharms Llc	213138	28 Nov 2034	patent
Otezla · 3 strengths apremilast	apremilast	Amgen Inc	205437	29 Nov 2034	patent

Dec 2034 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Quviviq · 2 strengths daridorexant hydrochloride	daridorexant hydrochloride	Idorsia	214985	2 Dec 2034	patent
Jardiance · 2 strengths empagliflozin	empagliflozin	Boehringer Ingelheim	204629	11 Dec 2034	patent
Synjardy Xr · 4 strengths empagliflozin; metformin hydrochloride	empagliflozin; metformin hydrochloride	Boehringer Ingelheim	208658	11 Dec 2034	patent
Doryx Mpc doxycycline hyclate	doxycycline hyclate	Mayne Pharma	050795	23 Dec 2034	patent